 |
 |
|||||
  |
 |
 |
 |
 |
 |
|
 |
|
Marcia Kean has close to 30 years of health care industry experience, including senior positions with pharmaceutical, biotechnology and medical service firms, non-profit research organizations, and consulting firms. As one of the first senior-level practitioners of communications in the biotech industry, she has pioneered good practices in the field, and has been a prominent author and speaker on key communications and valuation issues facing senior management. Most recently, Mrs. Kean has been active as an industry pioneer in defining and addressing the myriad issues and opportunities inherent in Genomic Medicine. In addition to founding FKH's new practice in this arena, she has been a frequent speaker and guest author on topics pertaining to this emerging field. Prior to her appointment in 2002 as Chief Executive Officer of Feinstein Kean Healthcare, Mrs. Kean had taken a “sabbatical” as the SVP-Commercialization at Ardais Corporation, a privately held clinical genomics firm. In that role, she led the initial commercialization of that company's drug discovery technology. From 1990 to 2001, Mrs. Kean served as founder and Managing Director of the Corporate Communications practice at Feinstein Kean Healthcare. In that role, she led a full-service U.S. and international corporate communications practice, with specialization in the definition and repositioning of corporate identities; planning and fulfillment of valuation potential; investor relations and media strategy and execution; and management of sensitive or challenging corporate issues. She assisted the CEOs and CFOs of numerous private companies in the process of preparing for and conducting successful IPOs. Mrs. Kean recruited, trained, and supervised a professional team that provided full services to dozens of private and public biotech and specialty pharmaceutical companies. From 1982 to 1990, Mrs. Kean served simultaneously as vice president, corporate communications of Damon Corporation (NYSE) and of its subsidiary, Damon Biotech (Nasdaq), one of the first biotech companies in New England. She was the first and only female officer in the history of Damon Corporation. Mrs. Kean was the only non-CEO to serve on the Emerging Companies Section Governing Board of BIO, the leading biotech industry organization, from 1998 to 2001. She was among the originating team that designed the successful BIO CEO and Investor Conference, now held annually. She served on the Steering Committee of BIO 2000 in Boston -- the largest convocation in the history of the biotech industry up to that time – and was appointed as the Chair of the Communications Committee for that event. Mrs. Kean holds an M.B.A. in finance from New York University and a |
|
||||
 |
||||||
|
|
|
|
|
